Clay Siegall

As a young man of 19, Clay Siegall saw his father stricken with cancer. After watching him suffer and struggle with the disease for the next 5 years until his death when Clay was 24, he decided that his life’s work would be dedicated to developing and improving the woefully lacking cancer-fighting methods and medications that had been the only thing available to help his father combat the deadly disease.

Fast forward to the 1980s. Clay Siegall makes good on his goals. Beginning in 1988, he held positions at the National Institute of Health and The National Cancer Institute from 1988-1991. From 1991-1997 he worked for the Bristol-Myers Squibb Pharmaceutical Research Institute.

In 1988 Clay Siegall became co-founder of Seattle Genetics, located in Bothell’s Cascade Business Park. Today he serves as President/CEO/Chairman of the company. Siegall holds fast to the integrity of Seattle Genetics, maintaining the company’s focus and steadfastly refusing to sell out to or be taken over by large corporations whose main focus is money rather than cancer treatment. Siegall stands firm in his dedication to the founding principles of Seattle Genetics: To work to produce consistently better and more effective cancer-fighting methods and treatments. Siegall does not content himself with a company that does nothing more than recycle pre-existing drugs that fight cancer; he focuses the attention of Seattle Genetics on researching, developing, and marketing new and consistently more effective drugs in the war on cancer. He is also dedicated to making these cancer treatments available worldwide.

Siegall has opened an office in Switzerland in order for Seattle Genetics to be able to oversee and continue to improve and expand it’s international marketing interests. I February, he set a plan in motion to acquire the international rights to commercialize a recently developed cancer-fighting drug. He invested $2 billion into this venture. The drug, developed by a New Jersey-based biopharmaceutical company called Immunomedics, appeared to be at the forefront of cutting-edge cancer treatment. Siegall’s venture, while unsuccessful in it’s primary focus. left no doubt that Seattle Genetics meant business when it came to their dedication to providing oncology medications and treatments on a global scale.

Last year, Seattle Genetics’ sales reached $418 million, a 50% increase in just 2 years’ time. IN the past 5 years, their stock prices have ore than tripled. Next year’s projections are toward a continued increase in both company earnings and stock revenue under the capable leadership of Clay Siegall.

Siegall has stated publicly that he looks forward to waking up each day and doing work that he is excited about. His main goal is to see cancer successfully treated globally.